Precipio IncNASDAQ:PRPO
- LAST PRICE6.2100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots5.8500/ 1
- Ask / Lots7.0000/ 5
- Open / Previous Close0.0000 / 6.2100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRPO |
|---|---|---|
| 09:32 ET | 500 | 6.48 |
| 09:56 ET | 100 | 6.175 |
| 11:08 ET | 600 | 6.0629 |
| 03:00 ET | 2068 | 6.2495 |
| 03:05 ET | 1500 | 6.4001 |
| 03:07 ET | 505 | 6.21 |
May 6, 2024
Precipio Secures a short-term $500K Credit Facility, from 5:00PM ET on Monday May 06, 2024 by Dow Jones
5:00PM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Precipio Inc | 9.1M | -1.7x | --- |
InnerScope Hearing Technologies, Inc. | 2.7M | 0.0x | --- |
21st North Inc | 2.2K | 0.0x | --- |
Micron Solutions Inc | 1.9M | -0.8x | --- |
Escalon Medical Corp | 1.4M | 7.2x | -13.51% |
LogicMark Inc | 1.8M | -0.1x | --- |
Company Information
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Contact Information
- Headquarters
- 12325 Emmet StOMAHA, NE, United States 68164-4243
- Phone
- 203-787-7888
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Richard Sandberg
- Chief Executive Officer, Founder, Director
- Ilan Danieli
- Interim Chief Financial Officer
- Matthew Gage
- Chief Operations Officer
- Ahmed Zaki Sabet
- Chief Legal Counsel and People Officer
- Miri Chiko-radomski
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.1M |
|---|---|
Revenue (TTM) | $15.8M |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.29 |
EPS | $-3.73 |
Book Value | $10.16 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -31.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
